|
18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrent
|
5R21CA139814-02
|
$236,417
|
$236,417
|
BENARD, FRANCOIS
|
BRITISH COLUMBIA CANCER AGENCY
|
|
1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
|
5R01CA101700-06
|
$364,626
|
$91,157
|
GLICKSON, JERRY
|
UNIVERSITY OF PENNSYLVANIA
|
|
4'-Substituted nucleoside analogs as anticancer drugs
|
5R01CA124952-03
|
$455,093
|
$455,093
|
SECRIST, JOHN
|
SOUTHERN RESEARCH INSTITUTE
|
|
8-Chloro-Adenosine for Treatment of CLL (IND 68,229)
|
5R21CA112907-02
|
$305,800
|
$305,800
|
WIERDA, WILLIAM
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A Companion Diagnostic for Prognosis of Kidney Cancer
|
N43CO100135-000
|
$199,597
|
$199,597
|
Gillespie, John
|
20/20 GENE SYSTEMS, INC.
|
|
A comprehensive pharmacogenetic study of sorafenib in renal cell carcinoma patien
|
5R21CA139280-02
|
$171,600
|
$171,600
|
INNOCENTI, FEDERICO
|
UNIVERSITY OF CHICAGO
|
|
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma
|
1K08CA137153-01A2
|
$163,080
|
$163,080
|
Collisson, Eric
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
|
5R21CA133884-02
|
$297,018
|
$297,018
|
SLINGERLAND, JOYCE
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
A novel compound to selectively protect normal tissues from chemotherapy
|
1R43CA137933-01A2
|
$147,830
|
$147,830
|
HAHN, KRISTINE
|
PERSCITUS BIOSCIENCES, LLC
|
|
A Phase I/II Trial of Eltrombopag in Elderly Acute Myeloid Leukemia Patients
|
1R21CA153018-01
|
$332,000
|
$332,000
|
Gewirtz, Alan
|
UNIVERSITY OF PENNSYLVANIA
|
|
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
|
5R21CA139473-02
|
$343,200
|
$343,200
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A Pilot Study of 5-FC and Genetically-Modified Neural Stem Cells to Treat Gliomas
|
5R21CA137639-02
|
$365,200
|
$365,200
|
PORTNOW, JANA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
|
5R01CA051578-18
|
$236,153
|
$236,153
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
|
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
|
1R01CA136743-01A2
|
$634,270
|
$634,270
|
HAQUE, REINA
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S6
|
$7,064,076
|
$494,485
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S7
|
$100,000
|
$7,000
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S8
|
$50,000
|
$3,500
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academic Training in Medical Oncology
|
5T32CA009297-27
|
$304,451
|
$91,335
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
ACOSOG Non Competing Renewal
|
5U10CA076001-14
|
$3,560,232
|
$2,278,548
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
Action of RB Pathway in Breast Cancer Therapy
|
1R01CA129134-01A2
|
$321,003
|
$321,003
|
KNUDSEN, ERIK
|
THOMAS JEFFERSON UNIVERSITY
|
|
Adaptable Polymer Micelles for Tumor Targeting
|
1R01CA129287-01A2
|
$305,637
|
$305,637
|
PARK, KINAM
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
|
5R01CA134844-02
|
$321,841
|
$321,841
|
MITCHELL, DUANE
|
DUKE UNIVERSITY
|
|
Adoptive T-Cell Therapy for Acute Leukemia
|
1R21CA132277-01A2
|
$320,588
|
$320,588
|
BALL, EDWARD
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Adrenocortical Cancer and Thyroid Carcinomas: Models with Unique Properties
|
ZIA BC 010626
|
$340,265
|
$85,066
|
Fojo, Antonio
|
CCR (NCI)
|
|
Adult Brain Tumor Consortium (ABTC)
|
5U01CA137443-02
|
$1,989,811
|
$1,989,811
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
Adult Leukemia Research Center
|
5P01CA018029-35
|
$4,628,534
|
$1,851,414
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Advanced Anatomic and Functional Response Assessment in Lung Cancer
|
7R01CA125143-04
|
$307,531
|
$101,485
|
Schwartz, Lawrence
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
5R01CA139032-02
|
$332,000
|
$332,000
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
AIDS and Cancer Specimen Resource Central Office and Data Coordinating Center
|
3U01CA096230-08S1
|
$100,000
|
$100,000
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
AIDS and Cancer Specimen Resource Central Office and Data Coordinating Center
|
5U01CA096230-08
|
$754,565
|
$754,565
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
2U01CA121947-04
|
$4,660,100
|
$4,660,100
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Alkyltransferase Inhibitors for Cancer Chemotherapy
|
5R01CA071976-15
|
$250,931
|
$250,931
|
Kanugula, Sreenivas
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
|
5R01CA125153-05
|
$253,704
|
$253,704
|
GANGJEE, ALEEM
|
DUQUESNE UNIVERSITY
|
|
Altered Arachidonic Acid Balance and Colon Cancer
|
5R01CA114635-05
|
$325,756
|
$162,878
|
Rosenberg, Daniel
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
American Academy of Cancer Education Annuel Meetings - 2009, 2010, 2011
|
5R13CA126454-05
|
$40,055
|
$40,055
|
VON GUNTEN, CHARLES
|
SAN DIEGO HOSPICE AND PALLIATIVE CARE
|
|
An Exploratory Study of Biologic and Pathophysiologic Efects of Radiation Therap
|
ZIA BC 010709
|
$271,230
|
$271,230
|
Warren, Katherine
|
CCR (NCI)
|
|
Analog Studies of 4-HPR and its Glucuronide
|
7R01CA049837-16
|
$322,452
|
$322,452
|
CURLEY, ROBERT
|
OHIO STATE UNIVERSITY
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722001-005
|
$1,340,000
|
$1,340,000
|
WHITE, JONATHAN
|
MIDWEST RESEARCH INSTITUTE KANSAS CITY:1
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722002-004
|
$290,000
|
$290,000
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE:1109097
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722003-004
|
$200,000
|
$200,000
|
WANG, JENNIE
|
SRI INTERNATIONAL:1110101
|
|
Analysis of Patient Tumor Responses to Apo2L/TRAIL
|
5R01CA108888-05
|
$309,799
|
$154,900
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Analysis of Redox Modulated Signaling Networks in Response to Ionizing Radiation
|
5R01CA136810-02
|
$304,194
|
$152,097
|
Furdui, Cristina
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Analysis of the leukemic stem cell niche in chronic myeloid leukemia
|
1K08CA138916-01A1
|
$156,444
|
$156,444
|
Krause, Daniela
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Analysis of the Novel Kinase ROR2: A New Molecular Target in Renal Cell Carcinoma
|
5F31CA132543-03
|
$28,008
|
$28,008
|
WRIGHT, TRICIA
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Anatomic and Biologic Staging of Breast Disease with MRI
|
5R01CA069587-13
|
$457,084
|
$457,084
|
Hylton, Nola
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Anti-topoisomerase drug action in yeast
|
2R01CA052814-16A2
|
$325,112
|
$325,112
|
NITISS, JOHN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Anti-tumor Activity of Sugar Analogs via Blocking Glycolysis vs Glycosylation
|
5R01CA037109-21
|
$343,254
|
$343,254
|
LAMPIDIS, THEODORE
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Anti-Tumor Mechanisms and Therapeutic Effects of Vitamin D
|
5R01CA067267-16
|
$431,016
|
$431,016
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
|
5R01CA112252-05
|
$464,274
|
$464,274
|
HURWITZ, HERBERT
|
DUKE UNIVERSITY
|
|
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
|
5R01CA098787-06
|
$270,237
|
$135,119
|
NAGLE, DALE
|
UNIVERSITY OF MISSISSIPPI
|
Total relevant funding to Chemotherapy for this search: $522,770,634
|